

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 2

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-31. (Cancelled).

32. (Currently Amended) A method of treating a patient suffering from a -for
the treatment of diseases caused by traumatic or compression injuries to injury of a
nervous tissuetissues, the method ~~comprising~~ comprises the step of administering to a
patient a therapeutically effective amount of a pharmaceutical composition comprising a
therapeutic agent selected from ginsenoside Rb₁, its metabolites and salts thereof.

33. (Currently Amended) The method of claim 32, wherein the therapeutically
effective amount of the pharmaceutical composition is capable of suppressing the
suppresses secondary degeneration of the injured nervous tissue tissues caused by
traumatic or compression injuries to the nervous tissues.

34. (Currently Amended) The method of claim 33, wherein the nervous
tissues are spinal cords tissue is a spinal cord.

35. (Currently Amended) The method of claim 32, wherein the therapeutically
effective amount of the pharmaccutical composition ameliorates -agent is capable
ameliorating paralysis or paraplegia caused by traumatic or compression injuries the
injury to the nervous tissuestissue.

36. (Currently Amended) The method of claim 35, wherein the nervous
tissues are spinal cords tissue is a spinal cord.

BOS2 499194_17

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 3

37. (Cancelled).

38 (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition is capable of suppressing the suppresses secondary degeneration of the nervous tissues caused by demyelination.

39. (Currently Amended) The method of claim 38, wherein the therapeutically effective amount of the pharmaceutical composition is capable of suppressing suppresses apoptosis or apoptosis-like cell death of oligodendrocytes.

40. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is administered intravenously to the patient.

41. (Previously Presented) The method of claim 32, wherein the pharmaceutical composition is administered in a single intravenous infusion or in a continuous intravenous infusion to the patient.

42. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition administered to the patient provides a concentration of 1 ng/ml or less of ginsenoside Rb₁, its metabolites or salts thereof ~~to in~~ the extracellular fluid ~~in of a lesion at a concentration of 1 ng/ml or less.~~

43. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition administered to the patient provides a concentration of 1 pg/ml or less of ginsenoside Rb₁, its metabolites or salts thereof ~~to in~~ the extracellular fluid ~~in of a lesion at a concentration of 1 pg/ml or less.~~

BOS2_499191_1/

M. Sakanaka, et al.
U.S.S.N. 09/913,669
Page 4

44. (Currently Amended) The method of claim 32, wherein the therapeutically effective amount of the pharmaceutical composition administered to the patient provides a concentration of 100 fg/ml or less of ginsenoside Rb₁, its metabolites or salts thereof to in the extracellular fluid in of a lesion at a concentration of 100 fg/ml or less.

45-51. (Cancelled).

52. (Currently Amended) The method of claim 32, wherein the ~~diseases caused by~~ traumatic or compression injuries to the nervous tissue of the patients ~~comprise cause~~ spinal cord injury, head injury, neurotrauma, cerebral hemorrhage, subarachnoid hemorrhage, peripheral nerve injuries, Parkinson's Disease, demyelinating diseases, retinal detachment, herniation of intervertebral disks, spinal canal stenosis, spondylolysis, slipping diseases, cervical spondylolysis, ossification of the posterior longitudinal ligament or facial nerve paralysis.

53. (Previously Presented) The method of claim 32, wherein the nervous tissues are spinal cords.

BOS2_499194_1/